Polynucleotides Injectable Market Size, Share & Forecast Analysis to 2030

The global polynucleotides injectable market size was valued at around USD 0.15 billion in 2025 and projected to grow at a significant CAGR of over 15% during the forecast period from 2026 to 2030. The market is experiencing robust growth, driven by increasing demand for minimally invasive aesthetic and regenerative treatments. Polynucleotide injectables are widely adopted for skin rejuvenation, tissue repair, and anti-aging applications due to their high biocompatibility, ability to enhance cellular regeneration, and prolonged moisturizing effects. Asia Pacific leads the market, supported by a high volume of cosmetic procedures, strong medical tourism in countries such as South Korea, China, and Japan, and early adoption of advanced injectable therapies. Expanding dermatology and aesthetic clinics, rising disposable incomes, and growing awareness of regenerative medicine further strengthen regional dominance, while ongoing product innovation and clinician acceptance continue to propel overall market growth globally.

Market Insights:

• The global polynucleotides injectable market was estimated at around USD 0.15 billion in 2025 and expected to expand at a CAGR of over 15% from 2026 to 2030.
• Driven by rising demand for minimally invasive and regenerative aesthetic treatments.
• Asia Pacific dominates the market, led by South Korea, China, and Japan.
• Increasing use in eye rejuvenation makes it the leading application segment.
• MedSpas are the largest end-use segment due to high procedure volumes and consumer preference for non-surgical aesthetics.
• Growing adoption for skin quality improvement rather than volume enhancement.
• Continuous innovation in high-purity and stabilized polynucleotide formulations.
• Expanding applications in hair restoration, scar repair, and post-procedure recovery.
• Strong clinician preference due to high biocompatibility and safety profile.
• Rising medical tourism and aesthetic awareness support market growth.
• Market competition focuses on product differentiation, clinical evidence, and regional expansion.

Market Snapshot:

Key Drivers Accelerating the Polynucleotides Injectable Market

The market is being strongly fueled by the growing preference for advanced, minimally invasive aesthetic and regenerative therapies as consumers increasingly prioritize treatments that enhance natural skin quality and stimulate cellular regeneration. Polynucleotide injectables promote fibroblast activity, boost collagen synthesis, improve hydration, and aid in tissue repair, making them highly attractive for facial rejuvenation, under-eye correction, scar revision, and even applications like hair restoration. Their favorable safety profile, minimal downtime, and strong practitioner acceptance have broadened usage across dermatology and aesthetic clinics globally, contributing to greater adoption by both patients and medical professionals seeking alternatives to traditional fillers and surgical procedures.

Another major growth driver is continuous innovation and heightened industry recognition, particularly in key aesthetic hubs like Asia Pacific. Clinicians and manufacturers are investing in improved polynucleotide formulations that offer enhanced efficacy and targeted results, while supportive regulatory pathways in several regional markets are expanding product availability. A notable recent development is that Plinest® was awarded “Injectable Product of the Year” at The Aesthetics Awards 2025, highlighting its patented Polynucleotides HPT® technology for driving cellular repair and enhanced skin and hair quality—a recognition that underscores growing clinical confidence and visibility for polynucleotide injectables in elite aesthetic circles.

Industry Trends Fueling the Polynucleotides Injectable Market Growth

A major trend shaping the market is the growing shift toward regenerative and biostimulatory injectables rather than traditional volumizing fillers. Polynucleotide injectables are increasingly favored because they work at a cellular level, stimulating fibroblast activity, collagen production, and tissue repair. This aligns well with evolving patient preferences for treatments that improve overall skin quality, elasticity, and hydration over time, rather than delivering immediate but temporary aesthetic changes. As a result, polynucleotides are becoming a core component of long-term skin rejuvenation and preventive anti-aging protocols.

Another important trend is the expansion of treatment indications beyond facial aesthetics. While facial rejuvenation remains the primary application, polynucleotide injectables are now widely used for under-eye correction, neck and décolletage rejuvenation, scar healing, post-laser recovery, and hair restoration. Practitioners are also integrating these injectables into combination therapies alongside hyaluronic acid fillers, energy-based devices, and skin boosters, creating more comprehensive and personalized treatment plans that address multiple skin concerns simultaneously.

The market is also witnessing strong growth in Asia Pacific, driven by high aesthetic procedure volumes, rapid adoption of innovative injectable therapies, and expanding medical tourism. Countries such as South Korea, China, and Japan are at the forefront of this trend due to advanced aesthetic infrastructure, skilled practitioners, and a strong consumer focus on skin quality and non-surgical cosmetic solutions. Increasing disposable incomes and the proliferation of specialized aesthetic clinics are further accelerating adoption across both metropolitan and emerging urban areas.

Finally, ongoing formulation innovation and clinical standardization are emerging as key trends. Manufacturers are investing in advanced purification techniques, optimized molecular structures, and improved delivery methods to enhance product safety, consistency, and treatment outcomes. At the same time, growing clinical research, practitioner training programs, and standardized treatment protocols are improving confidence among clinicians and patients alike. These developments are helping position polynucleotide injectables as a scientifically backed, mainstream solution within the broader medical aesthetics and regenerative medicine landscape.

Future Opportunities Reshaping the Polynucleotides Injectable Market’s Evolution

A significant opportunity in the polynucleotides injectable market comes from product innovation and new formulation launches that expand functional and aesthetic benefits beyond traditional uses. Manufacturers are developing next-generation polynucleotide injectables designed to enhance skin hydration, elasticity, and tissue regeneration, making them attractive for broader aesthetic and therapeutic applications. For example, Croma-Pharma recently introduced a new polynucleotide-based injectable called juvenus that targets skin hydration, elasticity restoration, and wrinkle reduction with an antioxidative mode of action, offering differentiated benefits across a range of skin types and treatment needs. This innovation not only strengthens product portfolios but also provides clinics with new treatment options that can appeal to patients seeking deeper rejuvenation and long-term skin health results.

Another compelling opportunity lies in strategic regulatory progress and market access expansions in high-growth regions, particularly in Asia Pacific and China. Regulatory approvals and registrations of polynucleotide materials as medical devices or therapeutic agents enable broader clinical use and encourage local manufacturing initiatives. Recently, HTL Biotechnology secured medical device registration in China for its “Sodium DNA Raw Material Main Document” (polynucleotides), advancing its role in medical aesthetics, wound repair, and tissue regeneration applications, which underscores the growing recognition of polynucleotides beyond cosmetic indications and supports market confidence among providers and investors. Such regulatory advancements help streamline product adoption, support clinician training programs, and open doors for new commercial partnerships, particularly in markets with rapidly increasing aesthetic and regenerative therapy demand.

Polynucleotides Injectable Market Challenges:

The polynucleotides injectable market faces several restraining factors that can limit its growth despite rising demand. One of the primary challenges is the lack of standardized regulatory frameworks across regions, which can delay product approvals and restrict market entry, especially in emerging economies. In addition, high treatment costs and limited reimbursement coverage make polynucleotide injectables less accessible to price-sensitive consumers, confining adoption largely to premium aesthetic clinics. Variability in clinical outcomes due to differences in formulation quality, practitioner expertise, and treatment protocols can also affect patient confidence. Moreover, limited long-term clinical data compared to well-established injectables such as hyaluronic acid fillers creates cautious adoption among conservative practitioners, while the need for specialized training further slows widespread penetration of these therapies.

Market Segments Insights:

By Application: The Eyes Segment Dominated the Global Polynucleotides Injectable Market in 2025

The global polynucleotides injectable market is bifurcated into application, end-use, and geography. On the basis of application, the eyes segment is the dominant application in the market, accounting for the largest share of demand globally. This dominance is driven by the early and visible signs of aging in the peri-ocular area, such as dark circles, fine lines, hollowing, and skin thinning, which are difficult to treat with conventional fillers. Polynucleotide injectables are particularly well-suited for this delicate region because they improve skin quality, hydration, and elasticity through regenerative mechanisms rather than adding volume, reducing the risk of puffiness or unnatural results. As a result, dermatologists and aesthetic practitioners widely prefer polynucleotides for under-eye rejuvenation and tear trough treatments.

In addition, high patient awareness and repeat treatment demand reinforce the dominance of the eyes segment. Patients often prioritize eye-area treatments due to their strong impact on facial appearance and perceived aging, leading to consistent procedure volumes across aesthetic clinics. The growing trend toward natural-looking, non-surgical rejuvenation further supports adoption, as polynucleotide injectables offer gradual, long-lasting improvement with minimal downtime. Combined with increasing practitioner confidence and expanding clinical protocols for peri-ocular applications, these factors firmly position the eyes segment as the leading contributor to the polynucleotides injectable market.

By End-Use: The MedSpas Sub-category Holds the Largest Share of the Global Polynucleotides Injectable Market

On the basis of end-use, the global polynucleotides injectable market is further segmented into MedSpas, aesthetic & cosmetic centers, and hospitals. The MedSpas segment is the dominant end‑use segment in the global market, accounting for the largest share of global demand. This dominance is largely due to the rising popularity of non-invasive and minimally invasive aesthetic procedures among a broad consumer base seeking anti-aging, skin rejuvenation, and regenerative treatments without the downtime or higher costs associated with surgical interventions. MedSpas provide a comfortable, spa-like environment combined with medical oversight, which appeals to clients looking for convenient, safe, and effective polynucleotide injectable treatments. Their focus on personalized treatment plans and combination therapies allows practitioners to address multiple skin concerns, further strengthening patient satisfaction and repeat visits.

Additionally, MedSpas benefit from growing consumer awareness and willingness to invest in wellness-driven aesthetics, which drives consistent procedure volumes and revenue generation in this segment. Unlike hospitals or traditional cosmetic clinics, MedSpas can target both high-end and mass-market clientele with flexible service offerings and packages, making them an ideal channel for promoting polynucleotide injectables. The integration of advanced skincare technologies, specialized training for staff, and marketing strategies that emphasize natural, regenerative results has solidified MedSpas as the leading platform for polynucleotide treatments, positioning this segment for continued growth and market leadership.

The polynucleotides injectable market research report presents the analysis of each segment from 2020 to 2030 considering 2025 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2026 to 2030.

Global Polynucleotides Injectable Market Segmentation:

By Application:

• Eyes
• Lips
• Forehead
• Jawline & Cheekbones
• Others

By End-Use:

• MedSpas
• Aesthetic & Cosmetic Centers
• Hospitals

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: The Asia Pacific is Accounted to Hold the Largest Share of Global Polynucleotides Injectable Market in 2025

As of 2025, The Asia Pacific region is the dominant segment in the polynucleotides injectable market, accounting for the largest share of global demand. This dominance is driven by rapidly growing medical aesthetics adoption, high cosmetic procedure volumes, and rising disposable incomes in key countries such as South Korea, China, and Japan. Asia Pacific has become a hub for non-invasive and minimally invasive aesthetic treatments, including polynucleotide injectables, due to strong cultural emphasis on youthful appearance, innovative beauty trends, and advanced aesthetic clinic infrastructure. Additionally, the region benefits from booming medical tourism, attracting international patients seeking high-quality, cost-effective skin rejuvenation and anti-aging treatments.

The market leadership in Asia Pacific is further reinforced by early adoption of innovative polynucleotide formulations and advanced clinical protocols. Clinics and aesthetic centers in the region actively implement cutting-edge regenerative therapies, and practitioners are increasingly trained in the precise use of polynucleotides for applications such as eye, lip, and cheek rejuvenation, as well as hair restoration. Moreover, governments in several countries have streamlined regulatory approvals for aesthetic injectables, facilitating easier market entry for manufacturers and fostering competitive product launches. Combined, these factors have positioned Asia Pacific as the largest and fastest-growing market for polynucleotide injectables globally, with strong growth prospects continuing into the coming years.

Competitive Landscape:

The market is moderately competitive and moderately concentrated, with a blend of established aesthetic biotech firms and specialized polynucleotide product manufacturers vying for share. Leading companies include PharmaResearch Products Co., Ltd., BioPlus Co., Ltd., AMEELA, Mastelli, DermaFocus, and LG Chem, which are recognized for comprehensive product portfolios and strong clinical presence in aesthetic and regenerative treatments. These companies compete on the basis of product quality (purity and formulation), clinical validation, safety profiles, and regulatory compliance, which are critical differentiators in an industry where practitioners and patients prioritize efficacy and outcomes. Regional leaders leveraging established dermatology networks and practitioner education initiatives hold competitive advantages through deeper market penetration and brand trust.

Competition in the market also involves innovation in formulations and delivery technologies. Firms are investing in hybrid products (e.g., polynucleotides combined with hyaluronic acid or growth factors) and refining extraction and stabilization processes to enhance performance and broaden therapeutic applications. Recent product introductions by key players highlight this trend, such as new-generation polynucleotide injectables targeting improved tissue regeneration in Europe and specialized hybrid formulations launched in Asia. Alongside innovation, strategic initiatives such as partnerships with dermatology clinics, expansions into high-growth regions, and enhanced R&D collaborations are shaping competitive dynamics as companies seek to differentiate themselves and capture emerging demand.

Key Companies:

• PharmaResearch Products Co., Ltd.
• BioPlus Co., Ltd.
• LG Chem Ltd.
• AMEELA
• Mastelli S.r.l.
• Pluryal (MD Skin Solutions S.A.)
• Promoitalia Laboratories S.p.A.
• Fox Pharma
• BR Pharm
• DermaFocus
• ZK MEDIGROUP CO. LTD.
• Dermax Co., Ltd.

Key Questions Answered by Polynucleotides Injectable Market Report

• Global polynucleotides injectable market forecasts from 2026-2030
• Regional market forecasts from 2026-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2026-2030 covering 15 major countries from the regions as mentioned above
• Polynucleotides injectable submarket forecasts from 2026-2030 covering the market by application, end-use, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level markets from 2026-2030
• Competitive Landscape and market positioning of top 10 players operating in the market